论文部分内容阅读
【目的】探讨前列腺素E1脂微球载体(Lipo-PGE1)制剂对慢性肾功能衰竭(CRF)患者血管紧张素Ⅰ(AngⅠ)、血管紧张素Ⅱ(AngⅡ),醛固酮(ALD)、血尿素氮(BUN)、血肌酐(Scr)和内生肌酐清除率(Ccr)的影响。【方法】对42例诊断为CRF的患者每13静滴或直接缓慢静推Lipo-PGE120~30μg,连续应用4周,检测患者治疗前后AngⅠ、AngⅡ、ALD、BUN、Scr和Ccr的变化。【结果】CRF患者治疗后AngⅠ、AngⅡ、ALD、BUN、Scr均较治疗前有明显下降(P<0.01),Ccr较治疗前有明显升高(P<0.01)。【结论】Lipo-PGEt可以使CRF患者的AngⅠ、AngⅡ、ALD减少,BUN和Scr明显降低,而Ccr明显增加,改善病人肾功能。
【Objective】 To investigate the effect of Lipo-PGE1 preparation on angiotensin Ⅰ, angiotensin Ⅱ, aldosterone (ALD), blood urea nitrogen (BUN) in patients with chronic renal failure (CRF) (BUN), serum creatinine (Scr) and endogenous creatinine clearance (Ccr). 【Methods】 Forty-two patients with CRF were treated with Lipo-PGE 120 or 30 μg intravenously or slowly for 4 weeks. The changes of AngⅠ, AngⅡ, ALD, BUN, Scr and Ccr before and after treatment were measured. 【Results】 The levels of AngⅠ, AngⅡ, ALD, BUN and Scr in CRF patients after treatment were significantly lower than those before treatment (P <0.01), and Ccr was significantly higher than those before treatment (P <0.01). 【Conclusion】 Lipo-PGEt can reduce the AngⅠ, AngⅡ, ALD, BUN and Scr in CRF patients, and significantly increase Ccr and improve renal function.